Henk J. Broxterman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Henk J. Broxterman has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Klaas Hoekman
VU University Medical Center
6 shared publications- Henk M.W. Verheul
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications Epie Boven
VU University Medical Center
3 shared publicationsGerrit Jan Schuurhuis
VU University Medical Center
3 shared publicationsVictor W. M. van Hinsbergh
VU University Medical Center
3 shared publicationsChad Gundy
2 shared publications
Latest Publications
- 18 February 2010
- Published by Elsevier in Drug Resistance Updates
- Vol. 13 (1-2) , 1
A message from the New Editor-in-Chief
- 18 February 2010
- Published by Elsevier in Drug Resistance Updates
- Vol. 13 (1-2) , 1
A message from the New Editor-in-Chief
- Open Access
- 15 December 2009
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (2) , 268-275
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Background: Methods: Results: Conclusion:
- 15 December 2009
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (2) , 268-275
Open AccessCD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Background: Methods: Results: Conclusion:
- 1 August 2009
- Published by Elsevier in Drug Resistance Updates
- Vol. 12 (4-5) , 114-126
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
- 1 August 2009
- Published by Elsevier in Drug Resistance Updates
- Vol. 12 (4-5) , 114-126
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
- Open Access
- 11 February 2009
- Published by Springer Nature in Angiogenesis
- Vol. 12 (1) , 69-79
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib
Mature circulating endothelial cell (CEC) as well as endothelial progenitor populations may reflect the activity of anti-angiogenic agents on tumor neovasculature or even constitute a target for anti-angiogenic therapy. We investigated the behavior of CECs in parallel with hematopoietic progenitor cells (HPCs) in the blood of renal cell cancer patients during sunitinib treatment. We analyzed the kinetics of a specific population of small VEGFR2-expressing CECs (CD45neg/CD34bright), HPCs (CD45dim/CD34bright), and monocytes in the blood of 24 renal cell cancer (RCC) patients receiving 50 mg/day of the multitargeted VEGF inhibitor sunitinib, on a 4-week-on/2-week-off schedule. Blood was taken before treatment (C1D1), on C1D14, C1D28, and on C2D1 before the start of cycle 2. Also plasma VEGF and erythropoietin (EPO) were determined. Remarkably, while CD34bright HPCs and monocytes decreased during treatment, CD34bright CECs increased from 69 cells/ml (C1D1) to 180 cells/ml (C1D14; P = 0.001) and remained high on C1D28. All cell populations recovered to near pre-treatment levels on C2D1. Plasma VEGF and EPO levels were increased on C1D14 and partly normalized to pre-treatment levels on C2D1. In conclusion, opposite kinetics of two circulating CD34bright cell populations, HPCs and small CECs, were observed in sunitinib-treated RCC patients. The increase in CECs is likely caused by sunitinib targeting of immature tumor vessels.
- 11 February 2009
- Published by Springer Nature in Angiogenesis
- Vol. 12 (1) , 69-79
Open AccessIncreased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib
Mature circulating endothelial cell (CEC) as well as endothelial progenitor populations may reflect the activity of anti-angiogenic agents on tumor neovasculature or even constitute a target for anti-angiogenic therapy. We investigated the behavior of CECs in parallel with hematopoietic progenitor cells (HPCs) in the blood of renal cell cancer patients during sunitinib treatment. We analyzed the kinetics of a specific population of small VEGFR2-expressing CECs (CD45neg/CD34bright), HPCs (CD45dim/CD34bright), and monocytes in the blood of 24 renal cell cancer (RCC) patients receiving 50 mg/day of the multitargeted VEGF inhibitor sunitinib, on a 4-week-on/2-week-off schedule. Blood was taken before treatment (C1D1), on C1D14, C1D28, and on C2D1 before the start of cycle 2. Also plasma VEGF and erythropoietin (EPO) were determined. Remarkably, while CD34bright HPCs and monocytes decreased during treatment, CD34bright CECs increased from 69 cells/ml (C1D1) to 180 cells/ml (C1D14; P = 0.001) and remained high on C1D28. All cell populations recovered to near pre-treatment levels on C2D1. Plasma VEGF and EPO levels were increased on C1D14 and partly normalized to pre-treatment levels on C2D1. In conclusion, opposite kinetics of two circulating CD34bright cell populations, HPCs and small CECs, were observed in sunitinib-treated RCC patients. The increase in CECs is likely caused by sunitinib targeting of immature tumor vessels.
- 31 October 2007
- Published by Elsevier in Drug Resistance Updates
- Vol. 10 (4-5) , 182-193
Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma
- 31 October 2007
- Published by Elsevier in Drug Resistance Updates
- Vol. 10 (4-5) , 182-193
Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma
- 1 August 2007
- Vol. 98 (2) , 440-50
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.
Circulating cells of several lineages are thought to participate in angiogenesis and tumor growth. Experimental studies in tumor-bearing mice have pointed to the potential importance of VEGF-responding circulating (endothelial) progenitor cells in tumor growth. We have studied circulating CD31- and/or CD34-positive cell populations with a low to moderate VEGFR2 expression in human volunteers and cancer patients. We recognized four cell populations, which were further characterized by their content of major hematopoietic progenitor, monocytic, endothelial and platelet markers. After establishing the test-retest stability of the measurements in nine patients, we determined the frequencies of the various cell populations in a group of 20 volunteers and 14 cancer patients. Two populations were markedly increased in cancer patients. Small CD45(neg)/CD34(bright)/VEGFR2+ cells amounted to 12 and 64 cells/ml (P < 0.0001), respectively, and 246/ml and 578/ml VEGFR2+/CD45(bright) (/CD14+) monocytic cells were present in controls and cancer patients, respectively (P = 0.017). A third population of CD45(dim)/CD34(bright)/VEGFR2(low) cells amounted to 25 and 30 cells/ml (P = 0.38). Unexpectedly, a population of mainly anucleated CD45(low)/CD31(bright)/CD41(bright) cells was present in numbers of 9,076 and 16,697/ml (P = 0.04) in volunteers and cancer patients, which contained a VEGFR2(low) (compared to IgG isotype control) expressing population amounting to 1,142 and 1,642 cells/ml (P = 0.12). This fourth population probably reflects large platelets. The role of the herein identified VEGFR2+ circulating cell populations deserve further investigation in cancer patients treated with VEGF(R)-targeted therapies. Quantification of such cell populations in the blood of tumor patients may be valuable to monitor the efficacy of anti-angiogenic treatment.
- 1 August 2007
- Vol. 98 (2) , 440-50
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.
Circulating cells of several lineages are thought to participate in angiogenesis and tumor growth. Experimental studies in tumor-bearing mice have pointed to the potential importance of VEGF-responding circulating (endothelial) progenitor cells in tumor growth. We have studied circulating CD31- and/or CD34-positive cell populations with a low to moderate VEGFR2 expression in human volunteers and cancer patients. We recognized four cell populations, which were further characterized by their content of major hematopoietic progenitor, monocytic, endothelial and platelet markers. After establishing the test-retest stability of the measurements in nine patients, we determined the frequencies of the various cell populations in a group of 20 volunteers and 14 cancer patients. Two populations were markedly increased in cancer patients. Small CD45(neg)/CD34(bright)/VEGFR2+ cells amounted to 12 and 64 cells/ml (P < 0.0001), respectively, and 246/ml and 578/ml VEGFR2+/CD45(bright) (/CD14+) monocytic cells were present in controls and cancer patients, respectively (P = 0.017). A third population of CD45(dim)/CD34(bright)/VEGFR2(low) cells amounted to 25 and 30 cells/ml (P = 0.38). Unexpectedly, a population of mainly anucleated CD45(low)/CD31(bright)/CD41(bright) cells was present in numbers of 9,076 and 16,697/ml (P = 0.04) in volunteers and cancer patients, which contained a VEGFR2(low) (compared to IgG isotype control) expressing population amounting to 1,142 and 1,642 cells/ml (P = 0.12). This fourth population probably reflects large platelets. The role of the herein identified VEGFR2+ circulating cell populations deserve further investigation in cancer patients treated with VEGF(R)-targeted therapies. Quantification of such cell populations in the blood of tumor patients may be valuable to monitor the efficacy of anti-angiogenic treatment.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 98 (08) , 440-450
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients
Circulating cells of several lineages are thought to participate in angiogenesis and tumor growth. Experimental studies in tumorbearing mice have pointed to the potential importance of VEGFresponding circulating (endothelial) progenitor cells in tumor growth.We have studied circulating CD31- and/or CD34-positive cell populations with a low to moderateVEGFR2 expression in human volunteers and cancer patients. We recognized four cell populations, which were further characterized by their content of major hematopoetic progenitor, monocytic, endothelial and platelet markers. After establishing the test-retest stability of the measurements in nine patients, we determined the frequencies of the various cell populations in a group of 20 volunteers and 14 cancer patients.Two populations were markedly increased in cancer patients. Small CD45neg /CD34bright/VEGFR2+ cells amounted to 12 and 64 cells/ml (Pbright (/CD14+) monocytic cells were present in controls and cancer patients, respectively (P=0.017). A third population of CD45dim/CD34bright/ VEGFR2low cells amounted to 25 and 30 cells/ml (P=0.38).Unexpectedly, a population of mainly anucleated CD45low/CD31bright/ CD41bright cells was present in numbers of 9,076 and 16,697/ml (P=0.04) in volunteers and cancer patients, which contained a VEGFR2low (compared to IgG isotype control) expressing population amounting to 1,142 and 1,642 cells/ml (P=0.12). This fourth population probably reflects large platelets. The role of the herein identified VEGFR2+ circulating cell populations deserve further investigation in cancer patients treated with VEGF(R)-targeted therapies. Quantification of such cell populations in the blood of tumor patients may be valuable to monitor the efficacy of anti-angiogenic treatment.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 98 (08) , 440-450
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients
Circulating cells of several lineages are thought to participate in angiogenesis and tumor growth. Experimental studies in tumorbearing mice have pointed to the potential importance of VEGFresponding circulating (endothelial) progenitor cells in tumor growth.We have studied circulating CD31- and/or CD34-positive cell populations with a low to moderateVEGFR2 expression in human volunteers and cancer patients. We recognized four cell populations, which were further characterized by their content of major hematopoetic progenitor, monocytic, endothelial and platelet markers. After establishing the test-retest stability of the measurements in nine patients, we determined the frequencies of the various cell populations in a group of 20 volunteers and 14 cancer patients.Two populations were markedly increased in cancer patients. Small CD45neg /CD34bright/VEGFR2+ cells amounted to 12 and 64 cells/ml (Pbright (/CD14+) monocytic cells were present in controls and cancer patients, respectively (P=0.017). A third population of CD45dim/CD34bright/ VEGFR2low cells amounted to 25 and 30 cells/ml (P=0.38).Unexpectedly, a population of mainly anucleated CD45low/CD31bright/ CD41bright cells was present in numbers of 9,076 and 16,697/ml (P=0.04) in volunteers and cancer patients, which contained a VEGFR2low (compared to IgG isotype control) expressing population amounting to 1,142 and 1,642 cells/ml (P=0.12). This fourth population probably reflects large platelets. The role of the herein identified VEGFR2+ circulating cell populations deserve further investigation in cancer patients treated with VEGF(R)-targeted therapies. Quantification of such cell populations in the blood of tumor patients may be valuable to monitor the efficacy of anti-angiogenic treatment.
- 1 August 2005
- Published by Elsevier in Drug Resistance Updates
- Vol. 8 (4) , 183-197
Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations
- 1 August 2005
- Published by Elsevier in Drug Resistance Updates
- Vol. 8 (4) , 183-197
Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations
- 1 April 2004
- Published by Elsevier in Drug Resistance Updates
- Vol. 7 (2) , 79-87
New cancer therapeutics: target-specific in, cytotoxics out?
- 1 April 2004
- Published by Elsevier in Drug Resistance Updates
- Vol. 7 (2) , 79-87
New cancer therapeutics: target-specific in, cytotoxics out?
- 1 February 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (3) , 1180-1191
Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts
Purpose: Expression of aminopeptidase N/CD13 can be detected in several solid tumor types. Thus far, the role of CD13 in ovarian cancer has not been studied. We have investigated the expression pattern and biological function of CD13 in ovarian cancer. Experimental Design: First, we studied the expression of CD13 in ovarian cancer tissue of 15 patients representing three different histological types (5 patients each) by immunohistochemistry. We then stably transfected the IGROV-1 human ovarian cancer cell line with a CD13 expression vector and examined the biological effect of CD13 in vitro and in vivo. Results: The expression of CD13 in ovarian cancer was associated with the histological subtype: CD13 expression in tumor cells was observed in 80–100% of the patients with a serous or mucinous carcinoma and in only 20% of the clear cell carcinoma patients. In all patients’ tumor samples, CD13-positive blood vessels were present. CD13 overexpression in IGROV-1 cells did not affect in vitro cell growth and sensitivity to doxorubicin, cisplatin, or gemcitabine. CD13 overexpression reduced invasion in Matrigel, which appeared to be independent of the aminopeptidase activity of CD13. Furthermore, the growth rate of IGROV-1/CD13 xenografts was reduced. The area of the vessel lumens was enlarged in a small percentage of vessels in the CD13-overexpressing xenografts. In addition, the CD13-overexpressing tumors were less sensitive to cisplatin. Conclusions: CD13 is expressed in tumor as well as endothelial cells in human ovarian cancer. Our results suggest that CD13 overexpression affects ovarian cancer growth, vascular architecture, and response to chemotherapy. Further elucidation of the mechanism of the observed effects of CD13 is warranted to better understand its role in the pathophysiology of ovarian cancer.
- 1 February 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (3) , 1180-1191
Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts
Purpose: Expression of aminopeptidase N/CD13 can be detected in several solid tumor types. Thus far, the role of CD13 in ovarian cancer has not been studied. We have investigated the expression pattern and biological function of CD13 in ovarian cancer. Experimental Design: First, we studied the expression of CD13 in ovarian cancer tissue of 15 patients representing three different histological types (5 patients each) by immunohistochemistry. We then stably transfected the IGROV-1 human ovarian cancer cell line with a CD13 expression vector and examined the biological effect of CD13 in vitro and in vivo. Results: The expression of CD13 in ovarian cancer was associated with the histological subtype: CD13 expression in tumor cells was observed in 80–100% of the patients with a serous or mucinous carcinoma and in only 20% of the clear cell carcinoma patients. In all patients’ tumor samples, CD13-positive blood vessels were present. CD13 overexpression in IGROV-1 cells did not affect in vitro cell growth and sensitivity to doxorubicin, cisplatin, or gemcitabine. CD13 overexpression reduced invasion in Matrigel, which appeared to be independent of the aminopeptidase activity of CD13. Furthermore, the growth rate of IGROV-1/CD13 xenografts was reduced. The area of the vessel lumens was enlarged in a small percentage of vessels in the CD13-overexpressing xenografts. In addition, the CD13-overexpressing tumors were less sensitive to cisplatin. Conclusions: CD13 is expressed in tumor as well as endothelial cells in human ovarian cancer. Our results suggest that CD13 overexpression affects ovarian cancer growth, vascular architecture, and response to chemotherapy. Further elucidation of the mechanism of the observed effects of CD13 is warranted to better understand its role in the pathophysiology of ovarian cancer.